A Global Asthma and COPD Drugs Market Size Study & Forecast, by Diseases (Asthma, COPD), by Medication Class (Combination Drugs, Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA)

Global Asthma and COPD Drugs Market Size Study & Forecast, by Diseases (Asthma, COPD), by Medication Class (Combination Drugs, Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Others), and Regional Analysis, 2023-2030

Global Asthma and COPD Drugs Market is valued at approximately USD 36.12 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 4.64% over the forecast period 2023-2030. Asthma and COPD drugs are medications used to manage and treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Both asthma and COPD are chronic respiratory diseases characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, shortness of breath, coughing, and chest tightness. The Asthma and COPD Drugs Market is expanding because of factors such as the growing trend of personalized therapy, changing lifestyle patterns, and increasing government support, coupled with better access to healthcare services.

In addition, the increasing prevalence of asthma and COPD is acting as a catalyzing factor for market growth across the globe. Asthma and COPD are chronic respiratory diseases with a significant global burden. According to the World Health Organization (WHO), respiratory disease infection is considered the third major cause of death with approximately 3 million death per year (6% of global deaths), in which nearly 90% of COPD fatalities occur in those 70-year-old people from the low-and middle-income countries. Also, there are around 262 million patients estimated to suffer from asthma, which commonly affects children. Thus, the increasing prevalence of these conditions, driven by factors such as air pollution, smoking, aging populations, and changing lifestyles, contributes to the growing demand for effective medications to manage and treat asthma and COPD, which, in turn, propelling the growth of the Asthma and COPD Drugs Market during the estimated period. Moreover, the technological advancements in drug development, as well as the increasing awareness about asthma and COPD, along with improved diagnostic techniques present various lucrative opportunities over the forecast years. However, the side effects associated with drugs and stringent government regulations for product approvals are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Asthma and COPD Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing research and development activities, along with the rise in the number of fundings undertaken by government and non-government organizations. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rising healthcare expenditure, favorable reimbursement policies, increasing aging population, as well as favorable reimbursement policies are significantly propelling the market demand across the region.

Major market players included in this report are:
Vectura Group Limited
Abbott Laboratories
Glaxosmithkline Plc
Sanofi
Organon
F. Hoffmann-La Roche AG
Novartis AG
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd
AstraZeneca Plc

Recent Developments in the Market:
In October 2022, Verona reported positive analyses of Ensifentrine, a medication used to treat chronic obstructive pulmonary disease (COPD), which was the subject of a phase 3 clinical trial. Ensifentrine combines bronchodilator and anti-inflammatory properties into a single substance.
In June 2022, Glenmark introduced the innovative fixed dose combination (FDC) medication Indacaterol with Mometasone for patients in India with unmanageable asthma. This FDC was introduced by the business under the Indamet brand.

Global Asthma and COPD Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Diseases, Medication Class, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Diseases:
Asthma
COPD

By Medication Class:
Combination Drugs
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Leukotriene Antagonists (LTA)
Anticholinergics
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa



Companies Mentioned
Vectura Group Limited
Abbott Laboratories
Glaxosmithkline Plc
Sanofi
Organon
F. Hoffmann-La Roche AG
Novartis AG
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd
AstraZeneca Plc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.